Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03952039
Other study ID # FEDR-MF-002
Secondary ID U1111-1223-29622
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 16, 2019
Est. completion date June 23, 2025

Study information

Verified date January 2024
Source Celgene
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.


Description:

This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF). This study will be conducted in compliance with International Council for Harmonisation (ICH) Good Clinical Practices (GCPs). Study design includes: - A 28-day Screening Period - 2:1 Randomization to fedratinib or best available therapy (BAT) - Stratification at Randomization according to: - Spleen size by palpation: < 15 cm below left costal margin (LCM) versus ≥ 15 cm below LCM - Platelets ≥ 50 to < 100 x 109/L versus platelets ≥ 100 x 109/L - Refractory or relapsed to ruxolitinib treatment versus intolerant to ruxolitinib treatment - Study Treatment Period (time on study drug plus 30 days after last dose) - Subjects are allowed to crossover from BAT to the fedratinib arm after the Cycle 6 response assessment or before the Cycle 6 response assessment in the event of a confirmed progression of splenomegaly by MRI/CT scan - A Survival Follow-up Period for progression and survival


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 202
Est. completion date June 23, 2025
Est. primary completion date December 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject is at least 18 years of age at the time of signing the informed consent form (ICF) 2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2 3. Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post-PV myelofibrosis according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report 4. Subject has a DIPSS Risk score of Intermediate-2 or High 5. Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of = 450 cm3 by MRI or CT-scan and by palpable spleen measuring = 5 cm below the left costal margin 6. Subject has a measurable total symptoms score (= 1) as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) 7. Subject has been previously exposed to ruxolitinib, and must meet at least one of the following criteria (a and/or b) 1. Treatment with ruxolitinib for = 3 months with inadequate efficacy response (refractory) defined as < 10% spleen volume reduction by MRI or < 30% decrease from baseline in spleen size by palpation or regrowth (relapsed) to these parameters following an initial response 2. Treatment with ruxolitinib for = 28 days complicated by any of the following (intolerant): - Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) or - Grade = 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib 8. Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to randomization 9. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted 10. Subject is willing and able to adhere to the study visit schedule and other protocol requirements 11. A female of childbearing potential (FCBP) must: 1. Have 2 negative pregnancy tests as verified by the Investigator during screening prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact. 2. Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with highly effective contraception without interruption, -14 days prior to starting investigational product, during the study treatment (including dose interruptions), and for 30 days after discontinuation of study treatment. Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). 12. A male subject must: Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 30 days following investigational product discontinuation, or longer if required for each compound and/or by local regulations, even if he has undergone a successful vasectomy Exclusion Criteria: 1. Any of the following laboratory abnormalities: 1. Platelets < 50 x 109/L 2. Absolute neutrophil count (ANC) < 1.0 x 109/L 3. White blood count (WBC) > 100 x 109/L 4. Myeloblasts = 5 % in peripheral blood 5. Estimated glomerular filtration rate < 30 mL/min/1.73 m2 (as per the Modification of Diet in Renal Disease [MDRD] formula) 6. Serum amylase or lipase > 1.5 x upper limit of normal (ULN) 7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN) 8. Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is < 25% of the total bilirubin 2. Subject is pregnant or lactating female 3. Subject with previous splenectomy 4. Subject with previous or planned hematopoietic cell transplant 5. Subject with prior history of encephalopathy, including Wernicke's (WE) 6. Subject with signs or symptoms of encephalopathy, including WE (eg, severe ataxia, ocular paralysis or cerebellar signs) 7. Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to the central laboratory and not demonstrated to be corrected prior to randomization 8. Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 3A4 (CYP3A4), or dual CYP2C19 and CYP3A4 inhibitors 9. Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids > 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to randomization 10. Subject has received ruxolitinib within 14 days prior to randomization 11. Subject with previous exposure to Janus kinase (JAK) inhibitor(s) other than ruxolitinib treatment 12. Subject on treatment with aspirin with doses > 150 mg daily 13. Subject with major surgery within 28 days prior to randomization 14. Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis) 15. Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to randomization. However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system), or is free of disease and on hormonal treatment only 16. Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4) 17. Subject with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC) 18. Subject with serious active infection 19. Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication 20. Subject is unable to swallow capsule 21. Subject with any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study 22. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study 23. Subject has any condition that confounds the ability to interpret data from the study 24. Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to randomization 25. Subject with a life expectancy of less than 6 months

Study Design


Intervention

Drug:
FEDRATINIB
A potent and selective inhibitor of JAK2 kinase activity
Best Available Therapy (BAT)
Best available therapy (BAT)

Locations

Country Name City State
Australia Local Institution - 101 Adelaide South Australia
Australia Local Institution - 105 Box Hill Victoria
Australia Local Institution - 103 Darlinghurst New South Wales
Australia Local Institution - 102 Frankston Victoria
Australia Local Institution - 100 Melbourne
Austria Local Institution - 156 Graz
Austria Local Institution - 154 Innsbruck
Austria Local Institution - 155 Linz
Austria Local Institution - 151 Salzburg
Austria Local Institution - 150 Vienna
Austria Local Institution - 153 Wels
Austria Local Institution - 152 Wien
Belgium Local Institution - 200 Brugge
Belgium Local Institution - 202 Bruxelles
Belgium Local Institution - 205 La Louvière-(Haine St-Paul)
Belgium Local Institution - 201 Leuven
Belgium Local Institution - 204 Liege
Belgium Local Institution - 203 Yvoir
China Local Institution - 555 Beijing
China Local Institution - 550 Guangzhou, Guangdong
China Local Institution - 553 Tianjin
China Local Institution - 557 Zhengzhou
Czechia Local Institution - 700 Brno
Czechia Local Institution - 702 Ostrava-Poruba
Czechia Local Institution - 701 Prague 2
France Local Institution - 255 Angers
France Local Institution - 256 Brest
France Local Institution - 254 Lens Cedex
France Local Institution - 259 Lille
France Local Institution - 260 Nice Cedex 3
France Local Institution - 250 Nimes Cedex 9
France Local Institution - 252 Paris
France Local Institution - 258 Pessac
France Local Institution - 257 Pierre-Benite
France Local Institution - 261 Poitiers Cedex
France Local Institution - 251 Strasbourg
France Local Institution - 253 Toulouse Cedex 9
Germany Local Institution - 302 Aachen
Germany Local Institution - 308 Frankfurt am Main
Germany Local Institution - 306 Halle
Germany Local Institution - 303 Jena
Germany Local Institution - 307 Magdeburg
Germany Local Institution - 301 Mannheim
Germany Local Institution - 304 Minden
Germany Local Institution - 305 Ulm
Hungary Local Institution - 600 Budapest
Hungary Local Institution - 601 Györ
Hungary Local Institution - 602 Kaposvar
Hungary Local Institution - 604 Nyiregyhaza
Hungary Local Institution - 603 Szeged
Ireland Local Institution - 751 Cork
Ireland Local Institution - 750 Dublin
Ireland Local Institution - 752 Dublin
Italy Local Institution - 353 Bologna
Italy Local Institution - 363 Brescia
Italy Local Institution - 354 Catania
Italy Local Institution - 350 Firenze
Italy Local Institution - 358 Milano
Italy Local Institution - 362 Naples
Italy Local Institution - 357 Pavia
Italy Local Institution - 356 Roma
Italy Local Institution - 359 Roma
Italy Local Institution - 361 Roma
Italy Local Institution - 355 Torino
Italy Local Institution - 360 Udine
Italy Local Institution - 352 Varese
Italy Local Institution - 364 Verona
Korea, Republic of Local Institution - 900 Seongnam-si
Korea, Republic of Local Institution - 901 Seoul
Korea, Republic of Local Institution - 902 Seoul
Korea, Republic of Local Institution - 903 Seoul
Korea, Republic of Local Institution - 904 Seoul
Korea, Republic of Local Institution - 905 Seoul
Netherlands Local Institution - 402 Maastricht
Netherlands Local Institution - 400 Nijmegen
Poland Local Institution - 803 Poznan
Poland Local Institution - 801 Warszawa
Poland Local Institution - 802 Wroclaw
Russian Federation Local Institution - 851 Moscow
Russian Federation Local Institution - 853 Moscow
Russian Federation Local Institution - 855 Moscow
Russian Federation Local Institution - 857 Novosibirsk
Russian Federation Local Institution - 852 Saint Petersburg
Russian Federation Local Institution - 854 Saint-Petersburg
Russian Federation Local Institution - 850 St Petersburg
Russian Federation Local Institution - 859 Vladikavkaz
Spain Local Institution - 451 Alicante
Spain Local Institution - 452 Badalona (Barcelona)
Spain Local Institution - 458 Barakaldo
Spain Local Institution - 450 Barcelona
Spain Local Institution - 462 Gerona
Spain Local Institution - 461 Las Palmas de Gran Canaria
Spain Local Institution - 453 Madrid
Spain Local Institution - 459 Madrid
Spain Local Institution - 457 Malaga
Spain Local Institution - 454 Murcia
Spain Local Institution - 455 Salamanca
Spain Local Institution - 463 Santa Cruz de Tenerife
Spain Local Institution - 460 Santiago de Compostela
Spain Local Institution - 456 Valencia
United Kingdom Local Institution - 502 Birmingham
United Kingdom Local Institution - 503 Boston
United Kingdom Local Institution - 501 London
United Kingdom Local Institution - 505 London
United Kingdom Local Institution - 504 Manchester Lancashire
United Kingdom Local Institution - 506 Nottingham Nottinghamshire
United Kingdom Local Institution - 500 Oxford

Sponsors (2)

Lead Sponsor Collaborator
Celgene Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Countries where clinical trial is conducted

Australia,  Austria,  Belgium,  China,  Czechia,  France,  Germany,  Hungary,  Ireland,  Italy,  Korea, Republic of,  Netherlands,  Poland,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Spleen Volume Response Rate (RR) Percentage of participants who have = 35% spleen volume reduction (SVR) at end of cycle 6
A Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment).
The RRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in RRs and 95% confidence interval of the difference for fedratinib to BAT.
From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days
Secondary Symptom Response Rate (SRR) Percentage of participants with = 50% reduction in total symptom scores measured by Myelofibrosis Symptom Assessment Form (MFSAF) 4.0 at end of cycle 6.
Subjects with a missing TSS at the end of cycle 6 or who had disease progression before the end of the cycle 6 will be considered non-responders.
MFSAF measures the sum of 7 symptoms on a scale from 0 to 10 (0 being absent and 10 being the worst imagineable). The lower the score the better.
A Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment).
The SRRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in SRRs and 95% confidence interval of the difference for fedratinib to BAT.
From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days
Secondary Spleen Volume Response Rate (RR25) Percentage of participants who have = 25% spleen volume reduction (SVR) at end of cycle 6
A Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment).
The RRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in RRs and 95% confidence interval of the difference for fedratinib to BAT.
From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days
Secondary Number of Participants With All Grade Treatment Emergent Adverse Events (AEs) and Grade 3 to 4 Treatment Emergent AEs Number of participants with all grade adverse events (AEs) and grade 3 to 4 AEs From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days
Secondary Number of Participants With Hematology Laboratory Abnormalities Number of participants with hematology laboratory abnormalities in the following parameters: hemoglobin (decreased), leukocytes (increase and decrease), lymphocytes (decreased), neutrophils (segmented and band form decreased), Platelets (decreased). From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days
Secondary Spleen Response Rate by Palpation (RRP) Spleen response rate by palpation is the percentage of participants at the end of cycle 6 with a spleen response according to the IWG-MRT 2013 criteria.
A baseline splenomegaly that is palpable at 5-10 cm, below the LCM, becomes not palpable** or A baseline splenomegaly that is palpable at > 10 cm, below the LCM, decreases by = 50%**
Participants with a missing spleen size assessment at the end of cycle 6 including those who meet the criteria for progression of splenomegaly before end of cycle 6 will be considered not to be responders.
From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days
Secondary Durability of Spleen Volume Response (DR) Durability of spleen volume response (DR) by MRI/CT is defined as the date from the first documented spleen response (ie, = 35% reduction in spleen volume) to the date of subsequent progressive disease (PD) in spleen volume per the IWG-MRT 2013 criteria or death, whichever is earlier. In the absence of an event before the analysis is performed, the DR will be censored at the date of the last valid assessment performed before the analysis performed date. From baseline to end of treatment visit, Approximately on average 53 weeks up to 151 weeks.
Secondary Durability of Spleen Response by Palpation (DRP) Durability of spleen response by palpation (DRP) is defined as time from the date of the first documented palpable spleen response, according to the IWG-MRT 2013 to the date of the subsequent PD in spleen size according to the IWG-MRT 2013 or death, whichever is earlier. Durability of spleen response by palpation according to the IWG-MRT 2013 criteria will be calculated for subjects that have an enlarged spleen at baseline (= 5 cm below LCM), and that have a spleen response by palpation. In the absence of an event before the analysis is performed, the DRP will be censored at the date of the last valid assessment performed before the analysis performed date. From baseline to end of treatment visit, Approximately on average 53 weeks up to 151 weeks.
Secondary Durability of Symptoms Response (DSR) The DSR is defined as time from the first documented response in TSS (ie, reduction in TSS = 50%) measured by MFSAF version 4.0 to the first documented TSS reduction < 50%. In the absence of TSS reduction < 50% before the analysis performed, the DSR will be censored at the date of the last valid assessment performed before the analysis performed date. From baseline to end of treatment visit, Approximately on average 53 weeks up to 151 weeks.
Secondary Assessment of the Effectiveness of Risk Mitigation Strategy for =3 Grade Gastrointestinal Adverse Events and Any Grade Wernickes Encephalopathy Number of participants with a CTCAE Grade =3 of nausea, diarrhea, or vomiting and any grade wernickes encephalopathy. From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days
Secondary Number of Participants With Thiamine Levels Below the Lower Limit of Normal Number of participants with thiamine levels below the lower limit of normal From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days
Secondary Mean Change in EORTC QOL-C30 at Cycle 7 Day 1 as Compared With Baseline QLQ-C30 - The EORTC QLQ-C30 was developed to assess the quality of life of cancer patients. It consists of 30 items classified into 15 domains including 5 functional subscales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning); 3 multi-item symptom subscales (fatigue, nausea/vomiting, and pain); a global QOL subscale; and 6 single items addressing various symptoms and perceived financial impact. Scores vary from 0 (worst) to 100 (best) for the functional dimensions and GHS, and from 0 (best) to 100 (worst) for the symptom dimensions. from the start of cycle 1 to cycle 7 day 1 approximately 170 days.
Secondary Mean Change From Baseline in EQ-5D-5L Utility Index Score EQ-5D-5L - The EQ-5D-5L is a generic, self-administered preference-based measure of health. The five dimensions covered by the EQ-5D-5L include mobility, self-care, pain, usual activities, and anxiety/depression and is converted into a single summary index that can range from -0.594 to 1.0, with a score of 0 indicating death, 1.00 indicating "full health," and negative scores reflecting states perceived to be worse than death. Respondent's self-rated health on a vertical, 0 to 100 scale where 100 = "Best imaginable health state" and 0 = "Worst imaginable health state" from the start of cycle 1 to cycle 7 day 1 approximately 170 days.
Secondary Time to Spleen and Disease Progression Free Survival (SDPFS) Time from randomization to death due to any reason or disease progression (modified IWG-MRT 2013 including = 25% increase in spleen volume by MRI/CT). From randomization to the End of Survival Follow-up
Secondary Overall Survival Time from randomization to death due to any reason From Randomization to the end of Survival Follow Up
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Phase 2
Completed NCT00069680 - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06397313 - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Phase 2
Not yet recruiting NCT06024915 - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02910258 - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00666549 - Research Tissue Bank
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1
Recruiting NCT04988815 - Ropeginterferon Alfa 2b for Early Myelofibrosis Phase 2